Healthcare >> CEO Interviews >> January 13, 2000
DR. SAMUEL WAKSAL is the President and Chief Executive Officer of
ImClone Systems Incorporated. Dr. Waksal spent the first part of his
career in academic medicine. From 1982 to 1985, he was a member of the
faculty of Mt. Sinai School of Medicine as Associate Professor of
Pathology and Director of the Division of Immunotherapy within the
Department of Pathology. Dr. Waksal has served as visiting Investigator
of the National Cancer Institute, Immunology Branch, Research Associate
of the Department of Genetics, Stanford University Medical School,
Assistant Professor of Pathology at Tufts University School of Medicine
and Senior Scientist for the Tufts Cancer Research Center. Dr. Waksal
was a scholar of the Leukemia Society of America from 1974 to 1984. Dr.
Waksal has published over fifty articles and chapters in the field of
Immunology. He has also helped found several biopharmaceutical companies
including Medicis Pharmaceutical Corporation, Cadus Pharmaceutical
Corporation and Merlin Pharmaceutical Corporation. He sits on the boards
of Cadus Pharmaceutical, Tribeca Pharmaceutical Corporation, Prototek II
and Microbes Incorporated. Dr. Waksal currently serves as Chairman of
New York Council for the Humanities Profile
Dr. Waksal: For more than a decade, ImClone has been focused on
developing a number of different products in multiple
